Archives

– ISA101b and cemiplimab studied in patients with platinum
refractory HPV16-positive oropharyngeal cancer (OPC)

Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals
B.V., a clinical-stage company dedicated to the development of rationally
designed immunotherapeutics, today announced randomization of the first
patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810).

This double blind, placebo-controlled, randomized,
phase 2 study (NCT03669718) will enroll approximately 164 patients with HPV16-positive oropharyngeal cancer (OPC), who have failed first-line chemotherapy. Patients will be randomly allocated on a 1:1 basis to the combination of cemiplimab/ISA101b or cemiplimab/placebo. In both study arms,

The publication describing the mechanism of improved immunogenicity of conjugation of AMPLIVANT titled “Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication,” by Gijs G. Zom et al. was selected as one of four noteworthy articles in the January edition of the JITC Digest. It reports novel murine data demonstrating the enhanced immunological potency of the novel TLR2-ligand, AMPLIVANT, as an adjuvant in cancer immunotherapy (Zom et al. 2018).

Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology
company, today announced that its Chief Scientific Officer Prof. Cornelis
Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in
Vancouver, BC, Canada, January 20-24, 2019.

The talk titled
“Therapeutic HPV16 Vaccination Is Effective as Monotherapy in
Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced
Cancers” is scheduled for Thursday, January 24, 2019, at 17:00 as part of the
session “Immune Monitoring of T Cells” (17:00-18-45, Pacific Ballroom).

The data will
outline the T cell response to ISA Pharmaceuticals´ therapeutic vaccine ISA101 and
the resulting clinical activity. ISA101 is directed against the HPV16 oncoproteins
E6/E7 and